Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394362 | 0.81 | ALDH1A1 (0.59) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL5387604 | 0.79 | ALDH1A1 (0.62) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL5398395 | 0.79 | ALDH1A1 (0.62) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7252958 | 0.76 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7252552 | 0.76 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7249022 | 0.76 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7248777 | 0.75 | USP2 (0.43) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7253857 | 0.74 | USP2 (0.38) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL7249608 | 0.72 | PAOX (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL5391357 | 0.70 | USP2 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6545022-B1 | Treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, neuropathological disorders, inflammatory diseases, and gastrointestinal disorders | PFIZER INC. | 2003-04-08 | — | — | US | disclosed |